Detalhe da pesquisa
1.
Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
Eur J Cancer
; 126: 1-10, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31887537
2.
Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.
Clin Colorectal Cancer
; 17(4): 313-319, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30463680
3.
Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity.
J Inorg Biochem
; 177: 249-258, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28551160
4.
Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.
J Clin Oncol
; 34(19): 2258-64, 2016 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27114605
5.
Hepatic encephalopathy associated with cancer or anticancer therapy.
Gastrointest Cancer Res
; 6(1): 11-6, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23505573
6.
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
J Clin Oncol
; 31(19): 2477-84, 2013 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23690424